The intended use of NPOSES (Nocturnal Pulse Oximetry Study Expert System) software is to collect, analyze, report and archive oximetry trend data to provide information to a Medical Doctor specializing in sleep medicine, as a supplemental tool to assist in the timely diagnosis of pediatric obstructive sleep apnea (OSA).

NPOSES is intended for use by an MD/Respiratory Specialist through the following process steps (1) recording and transferring data from a pulse oximeter to a computer in order to maintain unique records per patient of pulse oximetry data, (2) analyzing. reviewing and validating patient data and summary statistics according to customized. user-selected parameters, and (3) generating and archiving reports.

NPOSES in itself is not a diagnosis tool. It is a decision management tool which allows medical personnel to upload and view data related to a sleep study and provide output reports as feedback which may be used by an MD to form a diagnosis.

Device Description

The PHD Medical NPOSES (Nocturnal Pulse Oximetry Study Expert System) application scores data in the patient history, physician comments and test results to automatically produce an analysis report as input to the identification of pediatric obstructive sleep apnea which is presented to Respiratory Specialists and Medical Doctors. The suggested diagnosis is used to assist the Medical Director in the diagnosis of the severity of obstructive sleep apnea. The application enables the efficient processing of patient sleep evaluation studies while allowing the medical staff to concentrate on critical cases.

AI/ML Overview

The provided text describes a 510(k) submission for the NPOSES device, a Nocturnal Pulse Oximetry Study Expert System. However, it does not include detailed information regarding specific acceptance criteria for performance, the study design, or the results of a study to prove the device meets acceptance criteria.

The "Performance Data" section merely states: "Testing was performed to confirm that NPOSES software is capable of meeting all of its intended functional requirements. NPOSES passed all tests." This is a very high-level statement and does not provide the granular details requested.

Therefore, many of the requested fields cannot be filled from the provided text.

Here's a breakdown of what can be inferred and what is missing:

1. A table of acceptance criteria and the reported device performance

Acceptance Criteria	Reported Device Performance
Not specified	"NPOSES passed all tests."

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Sample size for test set: Not specified.
Data provenance: Not specified.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

Not specified. The device is intended to "automatically produce an analysis report as input to the identification of pediatric obstructive sleep apnea which is presented to Respiratory Specialists and Medical Doctors." This suggests the output is reviewed by experts, but the process of establishing ground truth for a test set is not described.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not specified.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No MRMC study is mentioned. The device is a "management tool" and a "supplemental tool to assist in the timely diagnosis," not an AI diagnostic tool that human readers would directly interact with to improve performance. The description focuses on its function in processing and organizing data.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

The device is explicitly stated as "not a diagnosis tool. It is a management tool which allows medical personal to input and view data relating to a study and give feedback which may be used by an MD to form a diagnosis." This implies it's not a standalone diagnostic algorithm, but rather a tool to generate output for a medical doctor specializing in sleep medicine. The "Performance Data" section vaguely states "NPOSES software is capable of meeting all of its intended functional requirements" and "NPOSES passed all tests," which likely refers to its functional capabilities (data processing, reporting) rather than diagnostic accuracy as a standalone algorithm.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

Not specified.

8. The sample size for the training set

Not specified. The document does not describe a machine learning model that would typically have a "training set" in the modern sense. It refers to an "Expert System" but does not detail how this system was developed or "trained."

9. How the ground truth for the training set was established

Not applicable/Not specified, as no training set or its ground truth establishment is described.

Summary

{0}------------------------------------------------

K060616

510(k) SUMMARY

Manufacturer's Name, Contact Person, Address, Phone, Fax, Email, Date Prepared

Mfr Name:	PHD Medical
Contact Name:	Tanima Ghosh
Postal Address.	500 Chemin Morgan, Suite 100
	Baie D'Urfé
	Québec H9X 3V1
	Canada
Phone:	514-694-0367
Fax:	514-694-4280
Email:	tanima.ghosh@phdmedical.com
Date Prepared:	January 6, 2006

Device Name, Common/Generic Name and Classification Name

Proprietary Name:	NPOSES
Common/Usual Name:	Pulse Oximeter Data Management Software
Classification Name:	Oximeter

Predicate DevicesnVISION Data Management Software (K033307), manufactured by Nonin Medical, Inc.

Description of the Device

Intended Use of the Device

The intended use of NPOSES (Nocturnal Pulse Oximetry Study Expert System) software is to provide information to a Medical Doctor specializing in sleep medicine to assist in the timely diagnosis of pediatric obstructive sleep apnea (OSA). NPOSES in itself is not a diagnosis tool. It is a management tool which allows medical personal to input and view data relating to a study and give feedback which may be used by an MD to form a diagnosis.

{1}------------------------------------------------

Technological Characteristics

The software will operate under Windows 98, Windows ME, Windows NT 4.0 with Service Pack 6 (SP6), Windows 2000, or Windows XP or later. Also under Linux: Debian, LinuxOS, Pack of (Sr o), Windows 2000, er in the predicate device can be used on a personal computer.

Performance Data

Testing was performed to confirm that NPOSES software is capable of meeting all of its intended functional requirements. NPOSES passed all tests.

Substantial Equivalence

NPOSES does not have a significant descriptive difference in comparison to the selected rs oble does marketed software device. There are no technological characteristics which impact prodicate maincouse betw. Based on our review of the candidate predicate device's description, surery and of one of enebel of performance specifications vs. NPOSES, it is concluded that NPOSES is substantially equivalent to the predicated device.

Conclusion

The cumulative test results demonstrated the functionality, safety and effectiveness of NPOSES, as well as its substantial equivalence to the predicate device.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the seal of the Department of Health and Human Services (HHS) of the United States. The seal features the department's name encircling a symbol. The symbol consists of a stylized caduceus, a staff with two snakes entwined around it, representing medicine and health. The seal is in black and white.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUN 2 9 2006

PHD Medical C/O Ms. Nancy Ruth Associate Director, Regulatory Services CanReg, Incorporated 4 Innovation Drive Dundas, ON CANADA L9H 7P3

Re: K060616

Trade/Device Name: NPOSES Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: II Product Code: DQA Dated: June 2, 2006 Received: June 5, 2006

Dear Ms. Ruth:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice. labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

Page 2 - Ms. Ruth

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

Chih-Lin, Ph.D.

Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Indications for Use

510(k) Number (if known):

Device Name: NPOSES

Indications For Use:

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
gn Offl
Page 1 of

ന വ് Anesthesiology, General Hospital,

con Control, Dental Devices

Nember ...

Regulation Number and Section

§ 870.2700 Oximeter.

(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).